Press release
DIEHARD Studio Release Mutant League Book
Mutant League Book Cover
The book also features humorous written commentary by Ferguson, who discusses the importance of design on elements such as backgrounds, props, uniforms and more.
Fans of the show will enjoy the tome, formatted in a fun 7.5 x 7.5 size that makes a great coffee table conversation book.
Ferguson is also the creator of the cult hit comic book series Hamster Vice and director of the action-packed short animated film Black Zero: Mercenary Ant. He is currently working with The Fresh Prince of Bel Air's Janet Hubert on the upcoming 3D animated short film “The Tell-tale Heart: Larynx Edition.
Art Directing Mutant League is available at www.diehardstudio.com.
For more information about the book “Art Directing Mutant League”, comics, graphic novels and more, please contact Lauren Ferguson via email at Lauren@diehardstudio.com.
DIEHARD Studio Entertainment is an independent production company, founded in 1986. The company produces animated films, 3D character design, concept art, and publish books.
Lauren Ferguson
DIEHARD Studio Entertainment
PO Box 399
Washington, NJ 07882
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release DIEHARD Studio Release Mutant League Book here
News-ID: 84674 • Views: …
More Releases from DIEHARD Studio Entertainment
The Tell-Tale Heart Will Haunt Your iPad
Washington, NJ -- Diehard Studio Entertainment is pleased to announce the release of the iPad adaptation of the Edgar Allan Poe classic, The Tell-Tale Heart. Perhaps Poe's finest story, The Tell-Tale Heart is a riveting tale told by an unnamed narrator who slowly reveals a chilling mystery.
The Tell-Tale Heart HD for iPad is an interactive, fully painted and fully voiced retelling of the classic Edgar Allan Poe horror tale. Illustrated…
Dash & Everest: a Very Kitten Christmas A Very Cute and Cuddly Children’s Book …
Washington, NJ (December 2010) -- Dwayne Ferguson, President & CEO of DIEHARD Studio, and the Art Director of the fan favorite hit animated TV series Mutant League, is pleased to announce the release of his new children’s book Dash & Everest: a Very Kitten Christmas. The story is cute and cuddly and will bring smiles of joy and delight to children.
Dash & Everest are BKFF (Best Kitten Friends Forever ®)!…
HAMSTER VICE RETURNS IN GRAPHIC NOVEL: COLLECTED MAYHEM
Washington, NJ – One of the most popular “funny animal” comics of the 80's returns in a nutritious collection, reprinting the first four issues of the series. Entitled Hamster Vice: Collected Mayhem, the volume contains 146 pages featuring the famous animal cop team. Also included is the rare mini-comic Killjoy Dragonslayer, which was originally only available at comic book conventions. The hilarious intro by comics legend Frank Thorne is…
More Releases for Mutant
BRAF Mutant Metastatic Melanoma Market Outlook 2024-2034: Targeted Therapies and …
In 2024, the global BRAF mutant metastatic melanoma market is estimated at USD 1.6 billion. By 2034, it is projected to reach USD 3.9 billion, growing at a CAGR of 9.2% (2025-2034). This strong expansion reflects increasing mutation testing rates, broader use of targeted inhibitors, and rising adoption of combination immunotherapies across key regions.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71180
Market Overview: Key Highlights
Market Size (2024): USD 1.6…
BRAF-mutant Non-Small Cell Lung Cancer Pipeline: 10+ Companies Advancing Targete …
The treatment landscape for BRAF-mutant Non-Small Cell Lung Cancer (BRAF+ NSCLC), a molecular subtype of NSCLC driven by mutations in the BRAF gene, most commonly the V600E mutation, is rapidly evolving. Traditionally associated with poor prognosis, BRAF+ NSCLC has witnessed significant clinical progress with the development of targeted therapies that inhibit aberrant MAPK pathway signaling. With growing recognition of the heterogeneity and aggressiveness of BRAF-driven tumors, biopharmaceutical companies are increasingly…
Mutant: The Digital Growth Catalyst for Startups
Image: https://www.abnewswire.com/uploads/3308ea53e26d2b7751959432f48accec.jpg
Are you a startup with a brilliant idea? Need a partner to transform your vision into a thriving business? Look no further than Mutant, the premier full-service digital agency. We deliver creative digital solutions that drive growth and help startups like yours navigate the complex digital landscape. Experience the power of our cutting-edge digital transformation services, empowering you to achieve sustainable development and ensuring your business stands out in…
HER2-mutant Non-Small Cell Lung Cancer Clinical Trials, Pipeline Insights, Treat …
DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the…
BRAF-mutant Non-Small Cell Lung Cancer Pipeline Insights, Clinical Trials, Treat …
DelveInsight's, "BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight 2024," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the BRAF-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline…
HER2-mutant Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical T …
DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the…
